社区

2024年5月17日 – 百奥赛图与GV Safety Assessment Platform（GVSAP）签署战略合作协议。GVSAP是GV Research Platform（GVRP）的子公司，总部位于印度海得拉巴医药城（Genome Valley），具有领先的综合研发平台，可提供全面的临床前研究解决方案。该合作的达成将为印度生物医药研发人员带来百奥赛图子品牌BioMice百奥动物的人源化小鼠等货架型模型以及基因编辑服务。详情可阅读下方新闻：

来源：

https://www.businesswireindia.com/gv-safety-assessment-platform-gvsap-and-biocytogen-forge-strategic-collaboration-to-accelerate-biopharmaceutical-innovation-90079.html

GV Safety Assessment Platform (GVSAP) and Biocytogen Forge Strategic Collaboration to Accelerate Biopharmaceutical Innovation

Hyderabad, Telangana, India – May 17, 2024 – GV Safety Assessment Platform (GVSAP), a leading integrated R&D enabler offering comprehensive preclinical research solutions, proudly announces a groundbreaking partnership with Biocytogen, a leader in industry-leading technologies that propel drug discovery. This collaboration marks a significant advancement in biomedical research, aimed at bolstering the R&D endeavors of Indian researchers by democratizing cutting-edge tools and technologies.

Through this strategic alliance, Indian biomedical researchers will gain unparalleled access to Biocytogen's expertise in providing Humanized research models, other Off-the-shelf models and products, and Gene Targeting Services offered under Biocytogen’s sub-brand BioMice.

Headquartered at Genome Valley, Hyderabad, GVSAP, a subsidiary of GV Research Platform (GVRP), boasts AAALAC International and OECD-GLP compliant facilities spanning over 30,000 square feet. With a state-of-the-art modern vivarium featuring dedicated SPF breeding and preclinical testing areas, GVSAP ensures the highest standards of research integrity and animal welfare.

Kalyan Korisapati, Co-Founder & CEO of GVRP, expressed his enthusiasm, stating, “Our company, GVSAP already serves as a preferred distributor of high-quality traditional and immunocompromised SPF rodents for customers in India. Our collaboration with Biocytogen marks a monumental milestone in our mission to propel biomedical innovation forward. Biocytogen’s expertise in creating engineered models that mimic the interaction between drug and human targets aims to provide the Indian Biopharma community with convenient access to precision research.”

Yuelei Shen, CEO of Biocytogen, emphasized the partnership's potential, stating, “Biocytogen empowers researchers with innovative tools and technologies. With India's rising prominence in biopharma R&D, it's a pivotal hub for advanced solutions like humanized mice. By leveraging GVSAP’s extensive reach in the Indian biopharma community, we are poised to catalyze pioneering discoveries and accelerate Indian biomedical research through this collaboration.”

By amalgamating GVSAP's global network, top-tier infrastructure, and skilled talent pool with Biocytogen's unparalleled expertise in genetic engineering and model development, the alliance aims to expedite the innovation of scientific discoveries.

For media inquiries and further information, please contact: info@gvrp.in or visit www.gvrp.in and https://en.biocytogen.com.cn/.

关于百奥赛图

百奥赛图（股票代码：02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地。基于底层基因编辑技术，百奥赛图自主研发了RenMice®（RenMab®、RenLite®、RenNano®、RenTCR-mimic™）平台，用于全人治疗性单克隆抗体、双/多特异性抗体、双抗ADC、纳米抗体和类TCR抗体的发现。百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发（“千鼠万抗™”计划），并已建立起40多万条全人抗体序列库，用于全球合作。截至2023年12月31日，百奥赛图已签署了103项药物合作开发/授权/转让协议并与包括多家MNC在内的企业达成了47个靶点项目RenMice®平台授权开发合作；多个临床阶段抗体分子也达成了对外授权合作。公司子品牌BioMice®提供几千种包括靶点人源化小鼠在内的基因编辑动物和细胞模型，同时为全球客户提供临床前药理药效和基因编辑服务。百奥赛图总部位于北京，在中国（江苏海门、上海）、美国（波士顿、旧金山）及德国海德堡等地设有分支机构。欲了解更多信息，请访问官网https://www.biocytogen.com.cn/。